Search

Targeted Chemotherapy? Platinum in BRCA1-Dysfunctional Breast Cancer — JCO

Targeted Chemotherapy? Platinum in BRCA1-Dysfunctional Breast Cancer — JCO
.....

Do these data suggest that we should incorporate platinum agents into adjuvant or neoadjuvant therapy in BRCA1 carriers? No. On the basis of currently available evidence, we cannot say that there is definitive evidence of a platinum benefit in triple-negative or even BRCA1-associated breast cancer, nor can we say that there is adequate evidence to routinely incorporate platinum agents into adjuvant or neoadjuvant therapy for any identifiable subtype of breast cancer. What we can say is that this is a reasonable avenue to pursue in prospective trials, and we can feel reassured that the clinical evidence thus far fits with preclinical models. With the advent of rational approaches developed from BRCA1-associated models, which we hope will be successfully applied to sporadic basal-like breast cancer, we will finally alter the prognostic landscape for patients with this disease.